Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. The company was founded in 2019 and is based in Toronto, Canada.
Metrics to compare | PSYG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPSYGPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −5.5x | −0.5x | |
PEG Ratio | 0.00 | −0.02 | 0.00 | |
Price/Book | −0.1x | −2.0x | 2.6x | |
Price / LTM Sales | - | 8.0x | 3.0x | |
Upside (Analyst Target) | - | 326.5% | 56.3% | |
Fair Value Upside | Unlock | −25.3% | 10.0% | Unlock |